We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+25.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$697M
AUM Growth
-$38.9M
Cap. Flow
-$135M
Cap. Flow %
-19.43%
Top 10 Hldgs %
45.64%
Holding
96
New
21
Increased
21
Reduced
26
Closed
24

Top Buys

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$12.7M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$8.91M
3
CCCC icon
C4 Therapeutics
CCCC
+$8.29M
4
CELC icon
Celcuity
CELC
+$7.84M
5
HCA icon
HCA Healthcare
HCA
+$7.74M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$27.1M
2
UTHR icon
United Therapeutics
UTHR
+$26.9M
3
CVS icon
CVS Health
CVS
+$18.4M
4
NVST icon
Envista
NVST
+$15.7M
5
LLY icon
Eli Lilly
LLY
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.09%
2 Consumer Staples 1.8%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
76
Biogen
BIIB
$30.7B
– –
-23,200
Closed -$6.19M
CSTL icon
77
Castle Biosciences
CSTL
$979M
– –
-297,840
Closed -$7.77M
FATE icon
78
Fate Therapeutics
FATE
$326M
– –
-67,300
Closed -$1.51M
IMUX icon
79
Immunic
IMUX
$195M
– –
-24,000
Closed -$758K
INMD icon
80
InMode
INMD
$880M
– –
-67,449
Closed -$1.96M
IOBT
81
DELISTED
IO Biotech
IOBT
– –
-288,119
Closed -$781K
IOVA icon
82
Iovance Biotherapeutics
IOVA
$2.83B
– –
-1,025,200
Closed -$9.82M
MIRM icon
83
Mirum Pharmaceuticals
MIRM
$6.14B
– –
-135,618
Closed -$2.85M
NRIX icon
84
Nurix Therapeutics
NRIX
$2.65B
– –
-504,144
Closed -$6.57M
NTRA icon
85
Natera
NTRA
$46.1B
– –
-275,673
Closed -$12.1M
NVO
86
Novo Nordisk
NVO
$209B
– –
-28,200
Closed -$1.41M
NVST icon
87
Envista
NVST
$4.52B
– –
-480,000
Closed -$15.7M
OSUR icon
88
OraSure Technologies
OSUR
$279M
– –
-565,000
Closed -$2.14M
PLRX icon
89
Pliant Therapeutics
PLRX
$65M
– –
-21,200
Closed -$443K
RCKT icon
90
Rocket Pharmaceuticals
RCKT
$394M
– –
-25,300
Closed -$404K
VRDN icon
91
Viridian Therapeutics
VRDN
$2.67B
– –
-19,518
Closed -$400K
VSTM icon
92
Verastem
VSTM
$592M
– –
-137,042
Closed -$1.4M
NVRO
93
DELISTED
NEVRO CORP.
NVRO
– –
-72,000
Closed -$3.35M
EIGR
94
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-7,300
Closed -$1.65M
DALS
95
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
– –
-50,000
Closed -$487K
APEN
96
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-1,137,105
Closed -$6.26M
1 2 3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Soleus Capital Management held 96 positions worth $697M, down 5.3% from $736M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Soleus Capital Management withdrew a net $135M in Q4 2022, closing 24 positions and reducing 26 holdings. Its most notable exit was Envista, an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Soleus Capital Management opened a new position in HCA Healthcare worth $8.29M.

  • Soleus Capital Management's largest Q4 2022 buy was HCA Healthcare: 34,550 shares worth $8.29M.
  • Soleus Capital Management added most to Vericel Corp in Q4 2022, an estimated $12.7M increase.
  • Soleus Capital Management's biggest Q4 2022 reduction was Illumina, cutting an estimated $27.1M.
  • Soleus Capital Management fully exited Envista in Q4 2022, selling an estimated $15.7M.
  • Soleus Capital Management's ten largest holdings make up 46% of its $697M portfolio in Q4 2022.
  • Soleus Capital Management opened 21 new positions and closed 24 in Q4 2022.
  • Soleus Capital Management's portfolio value fell 5.3% quarter-over-quarter to $697M.

Based on Soleus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.